Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gedatolisib with Paclitaxel and Carboplatin in Advanced Solid Tumors
NCT02069158Phase 1Completed
- Start
- Apr 2014
- Primary completion
- May 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of gedatolisib in breast cancer, non-small cell lung cancer (NSCLC), ovarian cancer and 3 more. Primary endpoints: Dose Limiting Toxicity at 28 days, Adverse Events at 8 weeks and 1 more. Started Apr 2014; status: completed.
02
Drugs
gedatolisib
03
Conditions
breast cancernon-small cell lung cancer (NSCLC)ovarian cancerendometrial cancer (EC)small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT02069158.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02069158.